Compumedics (ASX:CMP) said the US Food and Drug Administration cleared the Falcon home sleep testing device to be marketed in the US, according to a Wednesday Australian bourse filing.
The device will complement the firm's Somfit technology platform. Initial sales of the platform in the last six months were around AU$1 million.
The firm is currently targeting to achieve between 10% and 30% of the addressable market over the next 24 months.
Compumedics reaffirmed its guidance for the current fiscal year of revenues of at least AU$55 million and earnings before interest, taxes, depreciation, and amortization of about AU$5 million.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。